Company: SCYX
Filing Date: 2025-03-12
Form Type: 10-K
Source: 0000950170-25-038044
Chunk: 177

Company: SCYNEXIS INC
Filing Date: 2025-03-12
Form: 10-K
Item: Item 1B
Chunk 177
---
 No. 001-36365, and incorporated by reference here).

    10.28#
     
    Payoff Letter with Hercules Capital, Inc. dated May 25, 2023 (Filed with the SEC as Exhibit 10.1 to our Form 10-Q with the SEC on August 14, 2023, SEC File No. 001-36365, and incorporated by reference here).

    10.29#
     
    Binding Memorandum of Understanding for Amendment to Exclusive License Agreement and Transitional Manufacturing and Supply Agreement, dated as of December 26, 2023, by and between GlaxoSmithKline Intellectual Property (No. 3) Limited, and the Company (Filed with the SEC as Exhibit 10.41 to our Form 10-K with the SEC on March 28, 2024, SEC File No. 001-36365, and incorporated by reference here).

    10.30*
     
    Employment Agreement, dated November 15, 2017, between SCYNEXIS, Inc. and Scott Sukenick (Filed with the SEC as Exhibit 10.1 to our Form 10-Q, filed with the SEC on May 8, 2024, SEC File No. 001-36365, and incorporated by reference here).

    10.31*
     
    SCYNEXIS, Inc. 2024 Equity Incentive Plan.(Filed with the SEC as Exhibit 99.1 to our Form S-8, filed with the SEC on June 20, 2024, SEC File No. 333-280328, and incorporated by reference here).

    10.32*
     
    Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the SCYNEXIS, Inc. 2024 Equity Incentive Plan (Filed with the SEC as Exhibit 99.2 to our Form S-8, filed with the SEC on June 20, 2024, SEC File No. 333-280328, and incorporated by reference here).

    10.33*
     
    Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the SCYNEXIS, Inc. 2024 Equity Incentive Plan (Filed with the SEC as Exhibit 99.3 to our Form S-8, filed with the SEC on June 20, 2024, SEC File No. 333-280328, and incorporated by